Anti-Inflammatory Cream Reduces Skin Damage Induced by Ionizing Radiation

Abstract

The authors assessed whether the use of a topical anti‐inflammatory agent at the radiation entry site would prevent radiation‐induced skin damage and found that the use of a topical anti‐inflammatory agent, such as one containing 10% trolamine salicylate, may reduce skin damage at the radiation entry site if used prophylactically.

Accelerated senescence in skin in a murine model of radiation-induced multi-organ injury

“…Radiation, electrical and thermal burns all exhibit erythema, dry or moist desquamation, ulceration, and necrosis [2, 8, 9]. However, a defining characteristic of severe radiation burns is the occurrence of unpredictable cycles of inflammation that extend the initial damage, increasing the affected area of superficial epidermis and deeper tissues, as is delayed tissue necrosis and repair failure [2, 10]. It is hypothesized that repair failure in radiation skin injury is due to the loss of adult stem and progenitor cells [11].…”

MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review

“…Insufficient evidence was reported to support the use of urea, Xonrid, hydroactive colloid gel, and other interventions. 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 Topical corticosteroids 18 (15) 1715 (81; 12–219) Mometasone furoate (8); Betamethasone (6); Other (4) Breast (14); Head and neck (3); Multiple (1) Mometasone furoate and betamethasone were both generally found to be effective in ARD prevention. There is insufficient evidence supporting the use of other corticosteroids, such as hydrocortisone and beclomethasone.…”

“…A total of 42 studies assessed topical non-steroidal agents for the prevention of ARD, including 12 and 28 non-randomized studies and RCTs, respectively 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 ( Appendix C, Table 1 ). The majority of RCTs assessed trolamine-based products (including Biafine ®), 14 , 15 , 16 , 17 , 18 , 21 , 33 hyaluronic acid/hyaluronan-based products, 22 , 23 , 24 , 25 , 26 and heparinoid (Hirudoid ®).…”